Showing items 1 - 7 of 7

Your selections:

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma

- Carlino, Matteo S., Gowrishankar, Kavitha, Rizos, Helen, Saunders, Catherine A. B., Pupo, Gulietta M., Snoyman, Stephanie, Zhang, Xu Dong, Saw, Robyn, Becker, Therese M., Kefford, Richard F., Long, Georgina V.

CDKN2A common variants and their association with melanoma risk: A population-based study

- Debniak, T., Scott, Rodney J., Huzarski, T., Byrski, T., Rozmiarek, A., Debniak, B., Zaluga, E., Maleszka, R., Kladny, J., Gorski, B., Cybulski, C., Gronwald, J., Kurzawski, G., Lubinski, J.

Early stopping of clinical trials (Commentary)

- Cuzick, J, Howell, A, Forbes, John

Folic acid: vitamin and panacea or genetic time bomb?

- Lucock, Mark, Yates, Z.

Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer

- Tiller, K., Meiser, B., Gould, L., Tucker, K., Dudding, Tracy, Franklin, J., Friedlander, M., Andrews, L.

Naturopathy/herbalism consultations by mid-aged Australian women who have cancer

- Adams, Jon, Sibbritt, David, Young, Anne F.

The use of complementary and alternative therapies by patients with cancer

- Girgis, A., Adams, Jon, Sibbritt, David W.

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit